CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular IndicationZacks Investment Research • 06/24/25
Can Novo Nordisk Regain Ground After Cutting Ties With Hims & Hers?Zacks Investment Research • 06/24/25
Hims & Hers stock plummets after Novo Nordisk ends partnership over ‘knockoff' WegovyFast Company • 06/24/25
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to KnowThe Motley Fool • 06/24/25
Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbiditiesGlobeNewsWire • 06/23/25
Hims & Hers shares drop after Novo Nordisk ends Wegovy collaboration over compounding practicesProactive Investors • 06/23/25
Hims & Hers' stock plunges. Here's why Wegovy parent ended its partnership with the company.Market Watch • 06/23/25
Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketingPRNewsWire • 06/23/25
Novo Nordisk's new obesity drug hits high efficacy marks, but investors stay cautiousProactive Investors • 06/23/25
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of MedicineGlobeNewsWire • 06/22/25